Shuanglu Pharmaceutical announced on the evening of October 15 that the company recently received the “Drug Registration Certificate” for eptibatide injections approved and issued by the State Drug Administration. An eptibetide-specific platelet glycoprotein IIb/IIIa receptor antagonist can reverse ischemia caused by thrombosis by selectively and reversibly inhibiting the final common pathway of platelet aggregation. Clinically, it is mainly used for post-interventional antithrombotic treatment in patients with acute coronary syndrome, and can also be used to treat non-atherosclerotic angiopathy, thrombosis, etc.

Shuanglu Pharmaceutical announced on the evening of October 15 that the company recently received the “Drug Registration Certificate” for eptibatide injections approved and issued by the State Drug Administration. An eptibetide-specific platelet glycoprotein IIb/IIIa receptor antagonist can reverse ischemia caused by thrombosis by selectively and reversibly inhibiting the final common pathway of platelet aggregation. Clinically, it is mainly used for post-interventional antithrombotic treatment in patients with acute coronary syndrome, and can also be used to treat non-atherosclerotic angiopathy, thrombosis, etc.